Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients

被引：0
|
作者：
Bijal Shah
Jenny M. H. Chen
James J. Wu
Chaoling Feng
Lang Zhou
Julie E. Park
Tsveta Hadjiivassileva
Fabio R. Kerbauy
Sally W. Wade
Sam Keeping
机构：
[1] Moffitt Cancer Center,
[2] PRECISIONheor,undefined
[3] Kite,undefined
[4] a Gilead Company,undefined
[5] Federal University of Sao Paulo and Beneficência Portuguesa de São Paulo,undefined
[6] Wade Outcomes Research & Consulting,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Acute lymphoblastic leukemia; Chemotherapy; Blinatumomab; Brexucabtagene autoleucel; Brexu-cel; Indirect comparison; Inotuzumab ozogamicin; KTE-X19; MAIC; Standard of care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5383 / 5398
页数：15
相关论文
共 50 条
  • [1] Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients
    Shah, Bijal
    Chen, Jenny M. H.
    Wu, James J.
    Feng, Chaoling
    Zhou, Lang
    Park, Julie E.
    Hadjiivassileva, Tsveta
    Kerbauy, Fabio R.
    Wade, Sally W.
    Keeping, Sam
    ADVANCES IN THERAPY, 2023, 40 (12) : 5383 - 5398
  • [2] Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
    Shah, Bijal D.
    Cassaday, Ryan D.
    Park, Jae H.
    Houot, Roch
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Boissel, Nicolas
    Leguay, Thibaut
    Bishop, Michael R.
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha L.
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Subklewe, Marion
    Abedi, Mehrdad
    Minnema, Monique C.
    Wierda, William G.
    DeAngelo, Daniel J.
    Stiff, Patrick J.
    Jeyakumar, Deepa
    Mao, Daqin
    Adhikary, Sabina
    Zhou, Lang
    Schuberth, Petra C.
    Damico Khalid, Rita
    Ghobadia, Armin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (08)
  • [3] New European approval: Brexucabtagene autoleucel in adult relapsed/refractory acute lymphoblastic leukemia
    Lemoine, Jean
    Marchand, Tony
    BULLETIN DU CANCER, 2022, 109 (12) : 1232 - 1233
  • [4] The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    O'Connor, Timothy E.
    Lin, Chenyu
    Roloff, Gregory W.
    Zhang, Amy
    Aldoss, Ibrahim
    Faramand, Rawan
    Kopmar, Noam E.
    Dykes, Kaitlyn C.
    Jeyakumar, Nikeshan
    Dekker, Simone E.
    Gupta, Vishal K.
    Ahmed, Mohamed
    Logan, Aaron C.
    Zambrano, Hector
    Bradshaw, Danielle
    Mercadal, Santiago
    Schwartz, Marc
    Tracy, Sean
    Kubiak, Michal
    Mukherjee, Akash
    Majhail, Navneet
    Battiwalla, Minoo
    Mountjoy, Luke
    Malik, Shabaz
    Mathews, John
    Shaughnessy, Paul
    Ladha, Abdullah
    Yaghmour, George
    Advani, Anjali S.
    Stefan, Maryann
    Guzowski, Caitlin
    Hoeg, Rasmus T.
    Hilal, Talal
    Moore, Jozal
    Sasine, Joshua
    Solh, Melhem M.
    Lee, Catherine J.
    Kota, Vamsi K.
    Koura, Divya
    Veeraputhiran, Muthu
    Blunk, Betsy
    Leonard, Jessica T.
    Oliai, Caspian H.
    Bachanova, Veronika
    Stock, Wendy
    Cassaday, Ryan D.
    Shah, Bijal D.
    Miller, Katharine
    Muffly, Lori S.
    Galal, Ahmed
    BLOOD, 2023, 142
  • [5] FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Bouchkouj, Najat
    Lin, Xue
    Wang, Xiaofei
    Przepiorka, Donna
    Xu, Zhenzhen
    Purohit-Sheth, Tejashri
    Theoret, Marc
    ONCOLOGIST, 2022, 27 (10): : 892 - 899
  • [6] Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma
    Ionescu, Filip
    Faramand, Rawan
    Bailey, Hanna
    Bachmeier, Christina A.
    DiMaggio, Elizabeth
    Mohammed, Turab
    Isenalumhe, Leidy Lismeris
    Locke, Frederick L.
    Jain, Michael D.
    Shah, Bijal D.
    BLOOD, 2023, 142
  • [7] BREXUCABTAGENE AUTOLEUCEL FOR ADULT PATIENTS WITH REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA: COST-EFFECTIVENESS IN THE CLINICAL SUBSETS
    Marchetti, Monia
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 198 - 198
  • [8] Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Song, Jinlin
    Ma, Qiufei
    Gao, Wei
    Cong, Ze
    Xie, Jipan
    Zimmerman, Zachary
    Belton, Laura
    Franklin, Janet
    Palmer, Stephen
    ADVANCES IN THERAPY, 2019, 36 (04) : 950 - 961
  • [9] Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Jinlin Song
    Qiufei Ma
    Wei Gao
    Ze Cong
    Jipan Xie
    Zachary Zimmerman
    Laura Belton
    Janet Franklin
    Stephen Palmer
    Advances in Therapy, 2019, 36 : 950 - 961
  • [10] COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF RELAPSED/ REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN PATIENTS AGED 26 YEARS OR OLDER IN THE UNITED KINGDOM
    Spousta, T.
    Feng, C.
    van Hees, F.
    Wade, S.
    Doble, B.
    VALUE IN HEALTH, 2023, 26 (12) : S156 - S156
12345